In 2005 and 2006 we did the first double LTx in the world using marginal donor lungs evaluated ex vivo using ex vivo lung perfusion (EVLP) developed by Professor Stig Steen. Here we present a 10 year follow up comparing EVLP lungs with the conventional lungs performed at our clinic in the same year.Methods
Between 2005-2006, 21 patients (6 EVLP; 15 conventional) underwent LTx with follow-up until May 2016 at Lund University Hospital, Sweden. Pulmonary function was measured with spirometry and 6-minute walking test (6MWT) at 3, 6, 12 months and annually. Kaplan-Meier and Cox regression analyses was used to assess survival with death/re-lung transplantation as end-point.Results
No difference in median age nor gender distribution was shown between EVLP vs. conventional-LTx (p>0.05). Forced expiratory volume in 1 sec (FEV1) and 6MWT in 3, 6, 12 months and annually until 10-years is shown in image 1. No difference in median FEV1 nor 6MWT was found for EVLP vs. conventional-LTx (p>0.05). Survival curves for EVLP vs. conventional LTx for patients with a limited survival up to 5-years and overall survival up to 10-years respectively is shown (image 1). No significance was found (p>0.05). Same pattern was shown in subanalyses for patients with a limited survival up to 1-year and corresponding Cox regression analyses for 1-, 5- and 10-years (p>0.05).Conclusion
No superiority was found in conventional-LTx over EVLP LTx, neither in long-term survival nor pulmonary function. EVLP is a safe and effective method to use in LTx. EVLP has revalonated LTx and made it possible to improve marginal lungs but also to evaluate lungs post-mortem.